These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 32755586

  • 1. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
    Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M.
    Cell Rep; 2020 Aug 04; 32(5):107994. PubMed ID: 32755586
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.
    Cancer Sci; 2022 Jul 04; 113(7):2323-2335. PubMed ID: 35363931
    [Abstract] [Full Text] [Related]

  • 3. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2020 Apr 15; 38(2):360-368. PubMed ID: 31124056
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R.
    Mol Cancer Ther; 2017 Oct 15; 16(10):2130-2143. PubMed ID: 28751539
    [Abstract] [Full Text] [Related]

  • 7. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y, Matsumoto M, Takano N, Hirao M, Matsuda K, Tozuka T, Onda N, Nakamichi S, Takeuchi S, Miyanaga A, Noro R, Gemma A, Seike M.
    Cancer Med; 2024 Jun 15; 13(12):e7393. PubMed ID: 38923428
    [Abstract] [Full Text] [Related]

  • 8. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.
    J Thorac Oncol; 2015 Dec 15; 10(12):1670-4. PubMed ID: 26565381
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
    Chen Y, Steiner S, Hagedorn C, Kollar S, Pliego-Mendieta A, Haberecker M, Plock J, Britschgi C, Planas-Paz L, Pauli C.
    J Pathol; 2024 Jun 15; 263(2):257-269. PubMed ID: 38613194
    [Abstract] [Full Text] [Related]

  • 11. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 15; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 12. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A.
    Cancer Discov; 2016 Jan 15; 6(1):36-44. PubMed ID: 26546295
    [Abstract] [Full Text] [Related]

  • 13. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Regua AT, Bindal S, Najjar MK, Zhuang C, Khan M, Arrigo ABJ, Gonzalez AO, Zhang XR, Zhu JJ, Watabe K, Lo HW.
    Cancer Lett; 2024 Aug 10; 597():217023. PubMed ID: 38852701
    [Abstract] [Full Text] [Related]

  • 14. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 10; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 15. Evolving role of entrectinib in treatment of NTRK-positive tumors.
    Chawla N, Bui NQ, Seetharam M.
    Future Oncol; 2021 Aug 10; 17(22):2835-2846. PubMed ID: 33896226
    [Abstract] [Full Text] [Related]

  • 16. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI.
    Clin Lung Cancer; 2020 May 10; 21(3):247-254. PubMed ID: 31761448
    [Abstract] [Full Text] [Related]

  • 17. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ, Li GG, Kim ST, Hong ME, Jang J, Yoon N, Ahn SM, Murphy D, Christiansen J, Wei G, Hornby Z, Lee DW, Park JO, Park YS, Lim HY, Hong SN, Kim SH, Kang WK, Park K, Park WY, Kim KM, Lee J.
    Oncotarget; 2015 Nov 17; 6(36):39028-35. PubMed ID: 26472021
    [Abstract] [Full Text] [Related]

  • 18. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S.
    Expert Rev Anticancer Ther; 2020 May 17; 20(5):333-341. PubMed ID: 32223357
    [Abstract] [Full Text] [Related]

  • 19. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
    Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G.
    Mol Cancer Ther; 2018 Feb 17; 17(2):455-463. PubMed ID: 29237803
    [Abstract] [Full Text] [Related]

  • 20. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
    Mol Cancer Ther; 2016 Apr 17; 15(4):628-39. PubMed ID: 26939704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.